Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Venous Thrombosis

Free Subscription Articles published in Thromb Haemost Retrieve available abstracts of 89 articles: HTML format Text format

Single Articles

January 2019
1. COHEN AT, Agnelli G, Buller HR, Gallus A, et al
   Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
   Thromb Haemost. 2019 Jan 16. doi: 10.1055/s-0038-1676983.
   PubMed     Text format     Abstract available
   
   
   
2. KOSTRUBIEC M, Plywaczewska M, Jimenez D, Lankeit M, et al
   The Prognostic Value of Renal Function in Acute Pulmonary Embolism-A Multi-Centre Cohort Study.
   Thromb Haemost. 2019;119:140-148.
   PubMed     Text format     Abstract available
   
   
   
3. ZOLLER B, Pirouzifard M, Sundquist J, Sundquist K, et al
   Association of Short-Term Mortality of Venous Thromboembolism with Family History of Venous Thromboembolism and Charlson Comorbidity Index.
   Thromb Haemost. 2019;119:48-55.
   PubMed     Text format     Abstract available
   
   
   
4. SAMAMA CM
   Fast-Track Procedures in Major Orthopaedic Surgery: Is Venous Thromboembolism Prophylaxis Still Mandatory?
   Thromb Haemost. 2019;119:3-5.
   PubMed     Text format    
   
   
   December 2018
5. AGENO W, Haas S, Weitz JI, Goldhaber SZ, et al
   Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.
   Thromb Haemost. 2018 Dec 28. doi: 10.1055/s-0038-1676611.
   PubMed     Text format     Abstract available
   
   
   November 2018
6. PIAZZA G
   Oh Heavy Burden: Recognizing the Risk of Venous Thromboembolism in Women Undergoing Assisted Reproduction.
   Thromb Haemost. 2018 Nov 19. doi: 10.1055/s-0038-1676073.
   PubMed     Text format    
   
   
   
7. WEYCKER D, Li X, Wygant GD, Lee T, et al
   Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
   Thromb Haemost. 2018;118:1951-1961.
   PubMed     Text format     Abstract available
   
   
   October 2018
8. BORRE ED, Goode A, Raitz G, Shah B, et al
   Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.
   Thromb Haemost. 2018 Oct 30. doi: 10.1055/s-0038-1675400.
   PubMed     Text format     Abstract available
   
   
   
9. MONREAL M
   Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice.
   Thromb Haemost. 2018 Oct 17. doi: 10.1055/s-0038-1675241.
   PubMed     Text format    
   
   
   
10. PASTORI D, Violi F
    Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?
    Thromb Haemost. 2018 Oct 12. doi: 10.1055/s-0038-1675176.
    PubMed     Text format    
    
    
    
11. ROETKER NS, MacLehose RF, Hoogeveen RC, Ballantyne CM, et al
    Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673613.
    PubMed     Text format     Abstract available
    
    
    
12. GRANDONE E, Di Micco PP, Villani M, Colaizzo D, et al
    Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673402.
    PubMed     Text format     Abstract available
    
    
    
13. GRILZ E, Posch F, Konigsbrugge O, Schwarzinger I, et al
    Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673401.
    PubMed     Text format     Abstract available
    
    
    
14. ALBERTSEN IE, Nielsen PB
    Searching for High-Risk Venous Thromboembolism Patients Using Risk Scores: Adding to the Heap or Closing a Gap?
    Thromb Haemost. 2018;118:1686-1687.
    PubMed     Text format    
    
    
    August 2018
15. AGNELLI G, Becattini C, Bauersachs R, Brenner B, et al
    Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668523.
    PubMed     Text format     Abstract available
    
    
    
16. ROETKER NS, Lutsey PL, Zakai NA, Alonso A, et al
    All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668521.
    PubMed     Text format     Abstract available
    
    
    
17. PELLAND-MARCOTTE MC, Pole JD, Kulkarni K, Athale U, et al
    Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668543.
    PubMed     Text format     Abstract available
    
    
    
18. KRAAIJPOEL N, Di Nisio M, Mulder FI, van Es N, et al
    Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Thromb Haemost. 2018;118:1439-1449.
    PubMed     Text format     Abstract available
    
    
    
19. JIMENEZ D, Bikdeli B
    Scores to Identify Occult Cancer in Venous Thromboembolism: Do They Work?
    Thromb Haemost. 2018;118:1343-1344.
    PubMed     Text format    
    
    
    July 2018
20. PETTERSON TM, Smith CY, Emerson JA, Bailey KR, et al
    Venous Thromboembolism (VTE) Incidence and VTE-Associated Survival among Olmsted County Residents of Local Nursing Homes.
    Thromb Haemost. 2018;118:1316-1328.
    PubMed     Text format     Abstract available
    
    
    June 2018
21. KRAAIJPOEL N, van Es N, Raskob GE, Buller HR, et al
    Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study.
    Thromb Haemost. 2018 Jun 4. doi: 10.1055/s-0038-1649523.
    PubMed     Text format     Abstract available
    
    
    April 2018
22. FRERE C, Trujillo-Santos J, Font C, Samperiz A, et al
    Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry.
    Thromb Haemost. 2018 Apr 21. doi: 10.1055/s-0038-1642009.
    PubMed     Text format    
    
    
    
23. BAUERSACHS R, Lee AYY, Kamphuisen PW, Meyer G, et al
    Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
    Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641150.
    PubMed     Text format     Abstract available
    
    
    
24. BOURGUIGNON T, Bernard A, Fauchier L
    Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis.
    Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641167.
    PubMed     Text format    
    
    
    
25. HUGON-RODIN J, Horellou MH, Conard J, Gompel A, et al
    Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
    Thromb Haemost. 2018 Apr 3. doi: 10.1055/s-0038-1641152.
    PubMed     Text format     Abstract available
    
    
    
26. GOLDMAN S, Fraczek P, Szklanny K, Papuga-Szela E, et al
    Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
    Thromb Haemost. 2018;118:654-663.
    PubMed     Text format     Abstract available
    
    
    March 2018
27. KHORANA AA, Weitz JI
    Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Thromb Haemost. 2018 Mar 22. doi: 10.1160/TH17-09-0681.
    PubMed     Text format     Abstract available
    
    
    
28. CAMM AJ
    The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Thromb Haemost. 2018 Mar 22. doi: 10.1055/s-0038-1632387.
    PubMed     Text format     Abstract available
    
    
    
29. BARBERO E, Bikdeli B, Chiluiza D, Barrios D, et al
    Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism.
    Thromb Haemost. 2018 Mar 19. doi: 10.1055/s-0038-1637746.
    PubMed     Text format    
    
    
    
30. LEHNERT P, Lange T, Moller CH, Olsen PS, et al
    Acute Pulmonary Embolism in a National Danish Cohort: Increasing Incidence and Decreasing Mortality.
    Thromb Haemost. 2018;118:539-546.
    PubMed     Text format     Abstract available
    
    
    February 2018
31. LUTSEY PL, Horvath KJ, Fullam L, Moll S, et al
    Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1625985.
    PubMed     Text format     Abstract available
    
    
    
32. MARTOS L, Ramon LA, Oto J, Fernandez-Pardo A, et al
    alpha2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:alpha2M Levels Are Associated with Venous Thromboembolism.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1629902.
    PubMed     Text format     Abstract available
    
    
    
33. VAN DER POL LM, van der Hulle T, Mairuhu ATA, Huisman MV, et al
    Combination of Pulmonary Embolism Rule-out Criteria and YEARS Algorithm in a European Cohort of Patients with Suspected Pulmonary Embolism.
    Thromb Haemost. 2018 Feb 1. doi: 10.1055/s-0038-1623535.
    PubMed     Text format     Abstract available
    
    
    
34. SPRONK HMH, Padro T, Siland JE, Prochaska JH, et al
    Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
    Thromb Haemost. 2018;118:229-250.
    PubMed     Text format     Abstract available
    
    
    January 2018
35. BIKDELI B, Jimenez D, Hawkins M, Ortiz S, et al
    Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE).
    Thromb Haemost. 2018;118:214-224.
    PubMed     Text format     Abstract available
    
    
    
36. BLONDON M, Spirk D, Kucher N, Aujesky D, et al
    Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients.
    Thromb Haemost. 2018;118:82-89.
    PubMed     Text format     Abstract available
    
    
    December 2017
37. KLOK FA, Ageno W, Barco S, Binder H, et al
    Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
    Thromb Haemost. 2017;117:2425-2434.
    PubMed     Text format    
    
    
    
38. MEDINA A, Raskob G, Ageno W, Cohen AT, et al
    Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Thromb Haemost. 2017;117:2406-2414.
    PubMed     Text format    
    
    
    
39. RAUZI F, Smyth E, Emerson M
    Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo.
    Thromb Haemost. 2017;117:2283-2290.
    PubMed     Text format    
    
    
    
40. BYKOV K, Bohn RL, Ewenstein BM, Seeger JD, et al
    Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
    Thromb Haemost. 2017;117:2267-2273.
    PubMed     Text format    
    
    
    
41. LEE LH, Gallus A, Jindal R, Wang C, et al
    Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review.
    Thromb Haemost. 2017;117:2243-2260.
    PubMed     Text format    
    
    
    November 2017
42. HALTON JML, Picard AC, Harper R, Huang F, et al
    Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Thromb Haemost. 2017;117:2168-2175.
    PubMed     Text format     Abstract available
    
    
    
43. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117:2163-2167.
    PubMed     Text format     Abstract available
    
    
    
44. KHORANA AA, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117:2135-2145.
    PubMed     Text format     Abstract available
    
    
    
45. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117:2045-2052.
    PubMed     Text format     Abstract available
    
    
    October 2017
46. BASS AR, Fields KG, Goto R, Turissini G, et al
    Clinical Decision Rules for Pulmonary Embolism in Hospitalized Patients: A Systematic Literature Review and Meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
47. VAN OMMEN CH, Klaassen ILM, van Els AL, van de Wetering MD, et al
    Increasing Incidence and Recurrence Rate of Venous Thromboembolism in Paediatric Oncology Patients in One Single Centre Over 25 Years.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
48. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
49. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    September 2017
50. KHORANA A, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
51. SCHULMAN S
    Accumulating data on rivaroxaban for venous thromboembolism in clinical practice.
    Thromb Haemost. 2017;117.
    PubMed     Text format    
    
    
    August 2017
52. SEILER E, Limacher A, Mean M, Beer HJ, et al
    Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
53. MCBANE RD, Loprinzi CL, Ashrani A, Perez-Botero J, et al
    Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
54. BLEKER SM, Brekelmans MPA, Eerenberg ES, Cohen AT, et al
    Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
55. ANETSBERGER A, Blobner M, Haller B, Schmid S, et al
    Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
56. TAKACH LAPNER S, Julian JA, Linkins LA, Bates S, et al
    Comparison of clinical probability-adjusted D-dimer and age-adjusted D-dimer interpretation to exclude venous thromboembolism.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
57. JANION-SADOWSKA A, Natorska J, Siudut J, Zabczyk M, et al
    Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    June 2017
58. COLEMAN CI, Coleman C, Bunz TJ, Turpie AGG, et al
    Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
59. SCHULMAN S, Ageno W, Konstantinides SV
    Venous thromboembolism: Past, present and future.
    Thromb Haemost. 2017;117:1219-1229.
    PubMed     Text format     Abstract available
    
    
    
60. VAN DER HULLE T, van Es N, den Exter P, van Es J, et al
    Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability? A patient-level meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    May 2017
61. CHUNG WS, Lin CL
    Increased risks of venous thromboembolism in patients with psoriasis. A Nationwide Cohort Study.
    Thromb Haemost. 2017 May 24. doi: 10.1160/TH17-01-0039.
    PubMed     Text format     Abstract available
    
    
    April 2017
62. SANTI RM, Ceccarelli M, Bernocco E, Monagheddu C, et al
    Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
    Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895.
    PubMed     Text format     Abstract available
    
    
    
63. SCHULMAN S, Singer D, Ageno W, Casella IB, et al
    NOACs for treatment of venous thromboembolism in clinical practice.
    Thromb Haemost. 2017 Apr 20. doi: 10.1160/TH17-01-0065.
    PubMed     Text format     Abstract available
    
    
    
64. COHEN AT, Gitt AK, Bauersachs R, Fronk EM, et al
    The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
    Thromb Haemost. 2017 Apr 13. doi: 10.1160/TH16-10-0793.
    PubMed     Text format     Abstract available
    
    
    March 2017
65. RAJPURKAR M, Biss T, Amankwah E, Martinez D, et al
    Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review.
    Thromb Haemost. 2017 Mar 23. doi: 10.1160/TH16-07-0529.
    PubMed     Text format     Abstract available
    
    
    
66. SINDET-PEDERSEN C, Langtved Pallisgaard J, Staerk L, Gerds TA, et al
    Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
    Thromb Haemost. 2017 Mar 16. doi: 10.1160/TH16-10-0745.
    PubMed     Text format     Abstract available
    
    
    
67. TAFUR AJ, Caprini JA, Cote L, Trujillo-Santos J, et al
    Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-11-0840.
    PubMed     Text format     Abstract available
    
    
    
68. KLOK FA, Barco S, Konstantinides SV
    External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-10-0810.
    PubMed     Text format     Abstract available
    
    
    February 2017
69. 
    Erratum to Heit et al. "Reasons for the persistent incidence of venous thromboembolism" (Thromb Haemost 2017; 117: 390-400).
    Thromb Haemost. 2017;117:643.
    PubMed     Text format    
    
    
    
70. DENTALI F, Mumoli N, Prisco D, Fontanella A, et al
    Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.
    Thromb Haemost. 2017;117:606-617.
    PubMed     Text format     Abstract available
    
    
    
71. DING Q, Yang L, Zhao X, Wu W, et al
    Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.
    Thromb Haemost. 2017;117:479-490.
    PubMed     Text format     Abstract available
    
    
    
72. HEIT JA, Armasu SM, McCauley BM, Kullo IJ, et al
    Identification of unique venous thromboembolism-susceptibility variants in African-Americans.
    Thromb Haemost. 2017 Feb 16. doi: 10.1160/TH16-08-0652.
    PubMed     Text format     Abstract available
    
    
    
73. BREKELMANS MP, Scheres LJ, Bleker SM, Hutten BA, et al
    Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Thromb Haemost. 2017 Feb 9. doi: 10.1160/TH16-11-0874.
    PubMed     Text format     Abstract available
    
    
    
74. STUCK AK, Spirk D, Schaudt J, Kucher N, et al
    Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-08-0631.
    PubMed     Text format     Abstract available
    
    
    
75. BOCHENEK ML, Rosinus NS, Lankeit M, Hobohm L, et al
    From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-10-0790.
    PubMed     Text format     Abstract available
    
    
    January 2017
76. CHAI-ADISAKSOPHA C, Linkins LA, ALKindi SY, Cheah M, et al
    Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
    Thromb Haemost. 2017 Jan 12. doi: 10.1160/TH16-09-0680.
    PubMed     Text format     Abstract available
    
    
    
77. ZHAO B, Zhang Y, Huang Y, Yu J, et al
    A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
    Thromb Haemost. 2017;117:44-56.
    PubMed     Text format     Abstract available
    
    
    December 2016
78. HEIT JA, Ashrani A, Crusan DJ, McBane RD, et al
    Reasons for the persistent incidence of venous thromboembolism.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    November 2016
79. CHATTERJEE S, Weinberg I, Yeh RW, Chakraborty A, et al
    Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    
80. AY C, Pabinger I, Cohen AT
    Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    
81. AGENO W, Casella I, Han CK, Raskob GE, et al
    RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    October 2016
82. TRUJILLO-SANTOS J, Di Micco P, Dentali F, Douketis J, et al
    Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    
83. RIEDL J, Kaider A, Marosi C, Prager GW, et al
    Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    
84. AMBROSINO P, Tarantino L, Di Minno G, Paternoster M, et al
    The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    
85. 
    Venous thromboembolism: A Call for risk assessment in all hospitalised patients.
    Thromb Haemost. 2016;116:777-779.
    PubMed     Text format    
    
    
    
86. COHEN AT, Katholing A, Rietbrock S, Bamber L, et al
    Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    September 2016
87. 
    Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
    Thromb Haemost. 2016;116:775.
    PubMed     Text format     Abstract available
    
    
    
88. WEITZ JI, Haas S, Ageno W, Angchaisuksiri P, et al
    Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
89. CAPPATO R, Welsh R
    Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Venous Thrombosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: